NCT01480986View on ClinicalTrials.gov

IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2013

Conditions
Progression Free Survival of the Treatment
Interventions
DRUG

Irinotecan combined with cisplatin, octreotide lar

Phase 1 irinotecan 180mg/m\^2，ivgtt，90min，D1 Cisplatin 50 mg/m\^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，

Trial Locations (1)

Unknown

Beijing Tumor Hospital, Beijing

All Listed Sponsors
lead

Peking University

OTHER

NCT01480986 - IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC | Biotech Hunter | Biotech Hunter